The biology of the combretastatins as tumour vascular targeting agents.
about
Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison Combretastatin-A4A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cellsAntiangiogenic gene therapy of cancer: recent developmentsStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenograftsA combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor modelsAcute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressureTreatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancerTargeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.A robust approach to enhance tumor-selective accumulation of nanoparticles.Design, Synthesis and Cytotoxicity Evaluationof New 1,2-diaryl-4, 5, 6, 7-Tetrahydro-1H-benzo[d] Imidazolesas Tubulin Inhibitors.Role of the cytoskeleton in formation and maintenance of angiogenic sproutsDesign and synthesis of 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives as novel anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase.Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell deathDynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy.Site-Specific Drug-Releasing Polypeptide Nanocarriers Based on Dual-pH Response for Enhanced Therapeutic Efficacy against Drug-Resistant Tumors.Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division.A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells.Characterizing the tumor response to treatment with combretastatin A4 phosphate.Combretastatin A4 phosphate: background and current clinical status.Measuring tumour vascular response to antivascular and antiangiogenic drugs.Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.Anaplastic thyroid carcinomaSynthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.A novel microtubule-modulating agent EM011 inhibits angiogenesis by repressing the HIF-1α axis and disrupting cell polarity and migrationEffects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agentsCorrelation of hydrogen-bonding propensity and anticancer profile of tetrazole-tethered combretastatin analogues.Antivascular actions of microtubule-binding drugs.Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy.
P2860
Q24306494-67A3ADD8-83F6-4C79-B34D-1B3A23892494Q24622083-90B0A33A-526A-41EC-961F-61FF31790DE3Q24803786-2C4806B5-E7D3-442B-8F35-B1F03F6AB6F3Q26781365-D17BCA81-11A7-4476-984F-9712CC00153AQ28482576-95D4D9AD-7EBB-4CE8-8FE8-DD76597F1FCEQ28543671-4968F1AF-E6A0-4445-A258-847D1F7D986BQ33217481-EEC9F580-3D2B-4035-81DC-D0C5A9CCCEE9Q33265941-EEA6F832-2AB1-41A0-98E5-2921C94279FFQ33278296-7FAC86C0-2C17-453F-A35C-CE5D281355C1Q34279269-02EFC0C4-1078-469F-8C0D-0F9284D3E0BAQ34538659-378DAA3C-BA45-4FD1-9158-F5A21267411CQ34632966-F5B75B14-6685-476D-8E3E-AD32AC57CAD7Q34694874-8527AE4F-C81C-48C1-B8E8-B2FE1EDD03ADQ34754720-F003CAAE-6AFA-44E1-A1A7-6F1B2EFC9FA1Q34777723-A5B5F488-B034-4A7D-9897-CF051EB120C5Q34829230-E7DD0764-DAB8-4375-AF1A-DB8A4CC918C3Q34836054-87812B9D-3625-47DF-8943-6D802270B460Q35000792-635C8485-B557-4B1E-B904-50E5905EE0CBQ35056257-A8195288-FA6C-49B7-A08C-4D9BB825E6BDQ35077659-1A885130-FFE1-46B4-9122-EE08B071C1ECQ35488068-F26EA5E5-4F17-4E03-871A-87ABF31B3346Q35633363-2C300563-D3E3-40B8-81E8-D8944C990AC6Q35746819-7406ACBD-416D-452B-830B-ECFB8903C8FBQ35768905-6357BE8F-9806-487A-9591-4B4D74CA37A3Q35793182-9B33C6FF-2840-4A98-9298-CCACD21E9A30Q35871932-4248C340-F4A8-47B4-983D-449F910AC7C2Q35904992-443BCDFD-C185-4CC4-9941-491B1B7B2008Q35987317-017733C5-E92B-420B-B335-8F6813615EABQ36075843-3FB8A3B0-4C1B-4568-B076-A3E7467A92B7Q36243267-2F3EA960-3801-4564-A390-5AC0D95A7272Q36372894-C25E2DD7-B838-49F2-8B4C-DAA2F81BFEA1Q36445818-2C2BCFAA-A779-45D5-8B9B-A97CF7B73B3DQ36447016-2ACF1982-F0E0-411B-B8D2-C1CABBC9F11FQ36615531-22008430-E564-4858-8DB0-12D00F23191CQ36758604-4D7C898F-E21B-4419-A3A6-5CD256E02382Q36839418-363B48B6-A748-47CA-A5F0-20475315D792Q37174375-BB82C473-E608-4E17-B2F6-E567370C014FQ37349697-B1F15300-7ABF-45CC-8E07-F806B4747B6AQ37380736-FCDE9F37-3E5E-4D16-A79E-BADD7DCBF19AQ37541971-2625E83A-6F8D-4145-9172-D0F05EAE35C8
P2860
The biology of the combretastatins as tumour vascular targeting agents.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The biology of the combretastatins as tumour vascular targeting agents.
@ast
The biology of the combretastatins as tumour vascular targeting agents.
@en
The biology of the combretastatins as tumour vascular targeting agents.
@nl
type
label
The biology of the combretastatins as tumour vascular targeting agents.
@ast
The biology of the combretastatins as tumour vascular targeting agents.
@en
The biology of the combretastatins as tumour vascular targeting agents.
@nl
prefLabel
The biology of the combretastatins as tumour vascular targeting agents.
@ast
The biology of the combretastatins as tumour vascular targeting agents.
@en
The biology of the combretastatins as tumour vascular targeting agents.
@nl
P2093
P2860
P1476
The biology of the combretastatins as tumour vascular targeting agents.
@en
P2093
Charles S Parkins
Chryso Kanthou
Gillian M Tozer
Sally A Hill
P2860
P356
10.1046/J.1365-2613.2002.00211.X
P577
2002-02-01T00:00:00Z